Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, November 1999, p. 953-958, Vol. 6, No. 6
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Comparison and Characterization of Immunoglobulin G
Subclasses among Primate Species
Michael H.
Shearer,1
Robyn D.
Dark,2
James
Chodosh,3 and
Ronald
C.
Kennedy1,*
Departments of Microbiology and Immunology,
University of Oklahoma Health Sciences Center,1
and Ophthalmology and Molecular Pathogenesis of Eye Infection
Research Center, Dean A. McGee Eye Institute,3
Oklahoma City, Oklahoma 73104, and East Central University,
Department of Biology, Ada, Oklahoma 748202
Received 10 May 1999/Returned for modification 24 June
1999/Accepted 18 August 1999
 |
ABSTRACT |
Little information is available on the immunoglobulin G (IgG)
subclasses expressed in the sera of nonhuman primate species. To
address this issue, we compared the IgG subclasses found in humans
(IgG1, IgG2, IgG3, and IgG4) to those of nonhuman primates, such as
baboons and macaques. Cross-reactive antihuman IgG subtype-specific reagents were identified and used to analyze purified IgG from sera by
solid-phase enzyme-linked immunosorbent assay. Protein A-purified human
IgG obtained from sera was composed of IgG1, IgG2, IgG3, and IgG4,
whereas baboon and macaque IgG was composed of IgG1, IgG2, and IgG4.
Protein G-purified human IgG was composed of IgG1, IgG2, IgG3, and
IgG4, whereas baboon and macaque IgG was composed of IgG1, IgG2, and
IgG4. To test the possibility that baboon and macaque IgG3 is actually
present, but is outcompeted for binding to proteins A and G by the
other more abundant IgG subclasses, we repurified the IgG from sera
that did not bind either protein A or protein G. We found a baboon IgG3
population in the sera that did not bind protein A, but bound protein
G. No IgG3 subtype was detectable in macaque sera. These data suggest that baboon sera, like human sera, contain four IgG subtypes, whereas
macaque sera exhibit only three of the human subclass analogs. In
addition, the IgG subtype-specific reagents were shown to be useful in
determining the IgG subclass distribution following vaccination of
baboons with hepatitis B surface antigen.
 |
INTRODUCTION |
The use of animals to model human
disease has long been accepted as a substitute for using humans
(reviewed in references 24 and
37). The value of animals to the immunologist lies in their ability to produce immunological responses to infection and
immunization that are similar to those of humans. Small animals, such
as mice, rats, and rabbits, are commonly used to evaluate the
immunogenicity of vaccines and can provide important and cost-effective information in large experimental groups. However, small experimental animals may not be good predictors of human responses. In general, those animals most closely related to humans mimic more accurately the
human disease state and immunological response to infection and
vaccination (24).
Phylogenetically, the great apes are most closely related to humans
(reviewed in reference 37). The great apes include
chimpanzees, orangutans, gorillas, and gibbons. Next in evolutionary
distance are the Old World monkeys, which include mandrills, savannah
baboons, gelada baboons, mangabeys, African green monkeys, and
macaques. The most distantly related primate species compared to humans are the New World monkeys, which include the marmosets,
Aotus monkeys, capuchin monkeys, and squirrel monkeys.
One of the best-studied hominid nonhuman primates is the chimpanzee.
Chimpanzees represent valuable models of human disease. Examples of
situations in which chimpanzees have been used to model human infection
and disease include the human hepatitis A, B, and C viruses; human
immunodeficiency virus (HIV); respiratory syncytial virus (RSV); and
leprosy (1, 4, 9, 20, 22, 36). A variety of Old and New
World monkeys are susceptible to infection with various human
pathogens, but the issues of pathological consequence and mimicry of
the human disease state are less clear. Examples of these include
hepatitis A virus, hepatitis E virus, Epstein-Barr virus, RSV,
pertussis, measles virus, anthrax, Helicobacter pylori,
group B streptococcus, malarial parasites, HIV or simian immunodeficiency virus (SIV), and Ebola virus (3, 4, 6, 10, 12,
14, 15, 18, 19, 21, 25, 27-30, 41, 43, 46, 47, 51, 53, 57, 58).
Although the great apes are the most suitable model for studies of the
safety and efficacy of vaccines and treatment modalities destined for
human use, issues of cost, availability, and endangered species status
make the use of great apes less feasible. Thus, Old World monkeys
represent an attractive alternative.
In this study, we compare human immunoglobulin G (IgG) subclasses to
those of two Old World monkeys, the baboon (Papio
cynocephalus) and the macaque (Macaca fascicularis). By
utilizing anti-human IgG subtype cross-reactive reagents and a
combination of affinity purification methods, we demonstrate that,
similar to humans, baboons exhibit the IgG1, IgG2, IgG3, and IgG4
subclasses, while macaques exhibit only IgG1, IgG2, and IgG4. In
addition, we utilized the cross-reactive IgG subtype reagents to
examine the humoral immune response to vaccination with hepatitis B
surface antigen (HBsAg) in baboons. Our results indicate that the
predominant antibodies with responses to HBsAg (anti-HBs) were IgG1 and
IgG2, with the detection of some IgG4.
 |
MATERIALS AND METHODS |
Direct ELISA.
Briefly, individual wells of 96-well
microtiter plates were coated in triplicate with 50 µl of purified
human IgG myeloma subtypes (The Binding Site Limited, San Diego,
Calif.; Calbiochem-Novabiochem Co., San Diego, Calif.) at a
concentration of 4 µg/ml in borate-buffered saline (BBS). Three
different sets of individual myeloma proteins were examined. After
coating, nonspecific binding sites were blocked with 5% normal goat
serum (NGS) diluted in BBS, followed by washing the wells with BBS
supplemented with 0.05% Tween 20 (BBS-T). Fifty microliters of serial
dilutions of four horseradish peroxidase (HRP)-labeled anti-human IgG
subtype-specific reagents (The Binding Site Limited and
Calbiochem-Novabiochem Co.) diluted in NGS was then added to the wells
and incubated. We evaluated three different sets of HRP-anti-human IgG
subtype reagents. The plate was washed again with BBS-T, and 100 µl
of 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS)
substrate with 0.01% hydrogen peroxide was added. The enzyme-substrate
reaction was terminated by the addition of 100 µl of 10% sodium
dodecyl sulfate (SDS). The plates were read in an automated
enzyme-linked immunosorbent assay (ELISA) plate reader at an optical
density of 410 nm (OD410). These methods have been
described previously (45). The optimal dilution that demonstrated individual subtype specificity for the human IgG myeloma
proteins was selected for each of the HRP-anti-human IgG subtype
reagents. The same procedure was used to test protein A- and protein
G-purified IgG preparations; however, the coat concentration was
increased to 40 µg/ml.
Protein A and protein G affinity purifications.
Purification
of IgG from pooled sera (10 ml each) was performed by passing the sera
over either protein A or protein G immobilized on Sepharose. Individual
affinity columns were prepared by washing with BBS, followed by a mock
elution with 0.1 M glycine-HCl (pH 3.0), and then were equilibrated
with 1.5 M glycine-3 M NaCl buffer at pH 9.0 (binding buffer). Pooled
sera were mixed with an equal volume of binding buffer and passed over
the column five times. Unbound material was removed by washing with
binding buffer. Bound IgG was eluted in 1-ml fractions by using 0.1 M
glycine-HCl (pH 3.0). The fractions were read at OD280, and
fractions (
0.1) were pooled and dialyzed against BBS overnight. The
protein concentration was determined by taking the absorbance value at
OD280 and using an extinction coefficient of 13.6 for a
1.0% solution. This entire purification process was repeated with
pooled baboon and macaque sera. The purity of the IgG preparations was
assessed by SDS-polyacrylamide gel electrophoresis (reference
26 and data not shown).
Indirect ELISA.
The distribution of human and baboon
anti-HBs IgG subtypes was examined indirectly with the use of the
cross-reactive anti-human IgG subtype reagents. Briefly, HBsAg (Merck & Co., Inc., West Point, Pa.) was used to coat the solid phase of ELISA
microplate wells at 200 ng in 50 µl of BBS. The unreacted sites were
blocked with 5% NGS and washed with BBS-T, and a 1:50 dilution of sera from a human and baboons that had been vaccinated with HBsAg was added
to the HBsAg-coated wells. The antisubtype-HRP-labeled reagents were
added, and the ELISA was developed as described above.
Immunizations.
Baboons received three intramuscular
injections of recombinant HBsAg (Recombivax HB) as an alum precipitate
at monthly intervals as has been described elsewhere (54,
55). Serum was obtained prior to immunization and after the third injection.
 |
RESULTS |
IgG subclass determination.
We evaluated three different sets
of anti-human IgG subtype-specific reagents. We also utilized three
different sets of purified human IgG myeloma proteins representing the
four subclasses. In order to test the HRP-labeled probes for
reactivity, a direct ELISA was performed with the purified human IgG
myeloma proteins representing the different subclasses. Of the three
anti-IgG1-HRP probes, probe 3 demonstrated the best reactivity with all
three human IgG1 preparations based on OD410 (Table
1). In addition, background levels of
reactivity to the other (IgG2, IgG3, and IgG4) human myeloma proteins
were minimal compared to those of the probes with reactivity to the
IgG1 preparations. Of the anti-IgG2 probes, probe 3 reacted the best,
with an OD of 0.995 for the IgG2 preparation (designated coat 1). None
of the three anti-IgG2-HRP probes demonstrated good reactivity with the
IgG2 myeloma proteins, representing coats 2 and 3 (OD410,
<0.30). Background reactivity with probe 3 against IgG1, IgG3, and
IgG4 was minimal (OD410, <0.05). The anti-IgG3-HRP probes
demonstrated that probe 1 reacted the best with IgG3 myeloma proteins
designated coats 2 and 3 (OD, 2.000). Background reactivity to the
other IgG subclasses was minimal (<0.100). Of the anti-IgG4-HRP
probes, probe 3 exhibited the highest reactivity to the three IgG4
preparations and minimal reactivity to the other IgG myeloma proteins,
with all three coats exhibiting strong reactivity. Based on these data,
we selected the anti-IgG-HRP probes and the respective IgG myeloma
proteins as controls for subsequent studies.
Cross-reactivity of the anti-human IgG subtype probes with baboon
and macaque IgG.
Human, baboon, and macaque IgGs were individually
purified from sera by protein A and protein G affinity chromatography.
Each of the four anti-human IgG-HRP subtype probes reacted with protein A- and protein G-purified human IgG at OD410 values ranging
from 0.4 to 1.4 (Table 2). With protein
A-purified baboon IgG, the anti-IgG1 (0.299), anti-IgG2 (0.241), and
anti-IgG4 (0.136) probes were reactive, while the anti-IgG3 probe
appeared unreactive (0.056). Similarly, protein A-purified
macaque IgG exhibited reactivity with the anti-IgG1 (0.141), anti-IgG2
(0.151), and anti-IgG4 (0.151) probes, but not with the anti-IgG3
(0.022) probe. The protein G-purified baboon IgG demonstrated similar
reactivaties, with the anti-IgG1 (0.228), anti-IgG2 (0.167), and
anti-IgG4 (0.163) probes showing reactivity, while the anti-IgG3
(0.084) probe appeared unreactive. Similar results were obtained with
protein G-purified macaque IgG (Table 2). These results demonstrated
that baboons and macaques exhibit IgG1, IgG2, and IgG4 human-like
subclasses, but appear to lack IgG3.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Reactivity of antihuman IgG subtype-specific probes with
protein A- or protein G-purified human, baboon, and
macaque IgGa
|
|
Repurification of sera.
To test the possibility that baboon
and macaque IgG3 is actually present in sera and either may be
outcompeted for binding to the protein A and/or G by the more abundant
IgG subtypes or does not bind protein A or protein G, we performed
additional studies. Specifically, we repurified the sera that did not
bind protein A on protein G and repurified the sera that did not bind protein G on protein A. Human sera that did not bind protein G contained IgG1 (0.536), IgG2 (0.361), IgG3 (0.374), and IgG4 (0.590) populations that bound to protein A (Table
3). The human sera that did not bind to
protein A contained a significant population of IgG3 (1.066) that bound
to protein G, but little IgG1 (0.122), IgG2 (0.044), or IgG4 (0.063).
Interestingly, the baboon sera also exhibited an IgG3 (1.142)
population in the sera that did not bind protein A, but subsequently
bound protein G. No IgG3 was detectable in macaque sera by any of these
selective purification procedures. These data indicate that baboons,
like humans, exhibit four IgG subclasses, while macaques appear to lack
the IgG3 human subclass analog.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Reactivity of anti-human IgG subtype-specific probes with
protein A and protein G cross-purified human, baboon, and
macaque IgGa
|
|
Evaluation of the baboon antibody response to HBsAg
immunization.
Specifically, we analyzed the anti-HBs IgG subclass
response. Previous studies have demonstrated that the predominant IgG subclass observed in humans vaccinated with HBsAg was IgG1 (33, 34, 40). Sera from baboons were diluted 1:50 and tested for IgG
subtype distribution with an indirect ELISA. In Table
4, sera obtained from a pool of
vaccinated humans again demonstrated that IgG1 predominates in the
anti-HBs response. Pooled sera from HBsAg-immunized baboons also showed
that IgG1 had the predominant response. Next we evaluated the anti-HBs
IgG subclass distribution in individually immunized baboons. Baboons
exhibited a predominantly IgG1 and IgG2 anti-HBs response to HBsAg
vaccination (OD410 values of 0.231 to 0.407 and 0.210 to
0.382, respectively). HBsAg-immunized baboons also produced smaller
amounts of IgG4 anti-HBs, with little or no IgG3 being detected. These
data indicate that in baboons, IgG1 has predominance in response to
HBsAg immunization, similar to that in humans.
 |
DISCUSSION |
Each IgG subclass can exhibit its own set of functional
properties. For example, the IgG1 and IgG3 subtypes represent the predominant antibodies that react against protein antigens, such as the
toxins produced by pathogenic bacteria, and against a number of viral
agents. IgG2 responses have been shown to represent the predominant
response to the polysaccharide (Ps) capsule of certain disease-producing bacteria, like Haemophilus influenzae type
b. Some of the IgG subclasses are capable of efficiently crossing the
placenta and entering the fetal bloodstream, while others are less
efficient (35). IgG1 and IgG3 readily activate complement, while IgG2 is a weak activator and IgG4 fails to activate the complement cascade. IgG1 and IgG3 are cytophilic antibodies by virtue
of their ability to bind Fc receptors. These antibodies mediate
opsonization and can mediate killing by natural killer cells. The IgG2
and IgG4 subclasses either fail to exhibit these activities or do so
less efficiently than IgG1 and IgG3. Thus, the lack of a particular IgG
subclass may have an overall deleterious effect, and an individual may
be more susceptible to certain kinds of infections. This makes
knowledge of the IgG subtype distribution important for our
understanding of the specific immune responses to infection and
vaccination. Human IgG subclass distribution has also been utilized in
an attempt to characterize a particular immune response as being Th-1
or Th-2 like (31, 48).
Investigations have utilized the baboon as a nonhuman primate model for
assessing the safety and immunogenicity of candidate vaccines in
adults, pregnant females, and their infants (2, 5, 13, 38, 44, 52,
54, 56). The baboon was selected because of similarities to
humans in ontogeny, immunology, reproductive physiology, placentation,
and maternal-fetal transfer (7, 8, 16, 17, 39, 44, 49). The
advantages of the baboon over other commonly used simian primates, such
as macaques, include the ease of timed pregnancies due to the
estrogen-sensitive sex skin in cycling females, the comparative
availability because baboons breed year-round, the lack of
susceptibility to herpes B virus, the relative ease of handling, and
lower associated costs (reviewed in reference 23).
Reports decades old that used relatively insensitive immunologic
techniques suggested that baboons, like humans, exhibit four IgG
subclasses (7, 8). Other investigations suggested that macaque species exhibit only three IgG subclasses (32). Our data confirm more recent studies by other investigators that baboons and macaques exhibit four and three IgG subclasses, respectively (8, 32). We extend these findings and demonstrate that the macaque appears to lack the IgG3 subclass. The full complement of IgG
subclasses in baboons becomes important when selecting a nonhuman
primate model for immunologic investigations. The IgG3 subclass in
humans represents a cytophilic antibody that can activate complement,
and mediate opsonization and killing by natural killer cells. This
subclass of antibody can exhibit antimicrobial activities based on the
ability to mediate antibody-dependent cell-mediated cytotoxicity.
Investigations in humans have also reported that IgG3 can predominate
and may be associated with clinical immunity following infection with
Plasmodium falciparum (42, 50). Thus, the IgG3
subclass may play an important role in immunity to infectious agents.
The reasons we were unable to detect IgG3 in macaque sera remain to be
determined. An extensive search of the literature revealed only one
study in which a macaque IgG3 was detected (11). In this
study, macaques were immunized with intact oral microorganisms, and the
serum antibody response was evaluated by using anti-human IgG
subclass-specific probes. IgG3-specific responses were reported. The
possibility exists that macaques contain IgG3, and it is present at low
levels that were undetectable in our assays. Alternatively, the
anti-human IgG reagents employed may fail to cross-react with macaque
IgG3 preparations. It is also possible that the anti-human IgG3 subtype
reagents employed by other investigators cross-reacted with non-IgG3
subclasses in the macaque. In our evaluation of anti-human IgG subclass
reagents, we observed some cross-reactivity among different IgG myeloma
proteins with a particular reagent (unpublished observation) (Table 1).
The fact that we could detect IgG3 in baboons by similar methods
suggests that macaques may lack this particular subclass.
The present report describes a comparison of IgG subclasses among
humans, baboons, and macaques by using anti-human IgG subclass reagents. These reagents were also used to evaluate IgG subclass distribution in response to HBsAg immunization in baboons and humans.
Together these data further support the advantages of the use of
certain nonhuman primate species to model human immunologic situations.
 |
ACKNOWLEDGMENTS |
This work is supported in part by grants AI-35156, RR-12317, and
EY-00357 from the National Institutes of Health. J. Chodosh is the
recipient of a Career Development Award from Research To Prevent
Blindness, New York, N.Y.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, University of Oklahoma Health Sciences
Center, 800 N. Research Parkway, Suite 462, Oklahoma City, OK 73104. Phone: (405) 271-5630. Fax: (405) 271-6339. E-mail:
ronald-kennedy{at}ouhsc.edu.
 |
REFERENCES |
| 1.
|
Alford, P. L.,
D. R. Lee,
A. A. Binhazim,
G. B. Hubbard, and C. M. Matherne.
1996.
Naturally acquired leprosy in two wild born chimpanzees.
Lab. Anim. Sci.
46:341-346[Medline].
|
| 2.
|
Attanasio, R.,
J. S. Allan,
S. A. Anderson,
T. C. Chanh, and R. C. Kennedy.
1991.
Anti-idiotypic antibody response to monoclonal anti-CD4 preparations in nonhuman primate species.
J. Immunol.
146:507-514[Abstract].
|
| 3.
|
Barnett, S. W.,
K. K. Murthy,
B. G. Hendier, and J. A. Levy.
1994.
An AIDS-like condition induced in baboons by HIV-2.
Science
266:642-646[Abstract/Free Full Text].
|
| 4.
|
Belshe, R. B.,
L. S. Richardson,
W. T. London,
D. S. Sly,
J. H. Lorfeld,
E. Camargo,
D. A. Prevar, and R. M. Chanock.
1977.
Experimental respiratory syncytial virus infection of four species of primates.
J. Med. Virol.
1:157-162[Medline].
|
| 5.
|
Boulanger, D.,
G. D. Reid,
R. F. Sturrock,
I. Wolowczuk,
J. M. Balloul,
D. Grezel,
R. J. Pierce,
M. F. Otieno,
S. Guerret, and J. A. Grimaud.
1991.
Immunization of mice and baboons with the recombinant Sm28GST affects both worm viability and fecundity after experimental infection with Schistosoma mansoni.
Parasite Immunol.
13:437-490.
|
| 6.
|
Chang, S. P.,
S. E. Case,
W. L. Gosnell,
A. Hashimoto,
K. J. Kramer,
L. Q. Tam,
C. Q. Hashiro,
C. M. Nikaido,
H. L. Gibson,
C. T. Lee-Ng,
P. J. Barr,
B. T. Yokota, and G. S. N. Hui.
1996.
A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.
Infect. Immun.
64:253-261[Abstract].
|
| 7.
|
Damian, R. T.,
N. D. Greene, and S. S. Kalter.
1971.
IgG subclasses in the baboon (Papio cynocephalus).
J. Immunol.
106:246-257[Abstract/Free Full Text].
|
| 8.
|
Del Portillo, H. A.,
G. W. Schmidt, and R. T. Damian.
1987.
Immunochemical analysis of baboon Papio cynocephalus IgG subclass.
Vet. Immunol. Immunopathol.
16:201-214[Medline].
|
| 9.
|
Desrosiers, R. C.
1995.
Non-human primate models for AIDS vaccines.
AIDS
9:5137-5145.
|
| 10.
|
Desrosiers, R. C.,
M. D. Daniel, and Y. Li.
1989.
HIV-related lentiviruses of nonhuman primates.
AIDS Res. Hum. Retroviruses
5:465-473[Medline].
|
| 11.
|
Ebersole, J. L.,
G. R. Bauman,
S. E. Cox-O'Dell, and A. Giardino.
1997.
Evidence for serum immunoglobulin G (IgG) antibody responses in Macaca fascicularis identified by monoclonal antibodies to human IgG subclasses.
Oral Microbiol. Immunol.
12:193-203[Medline].
|
| 12.
|
Fritz, D. L.,
N. K. Jaax,
W. B. Lawrence,
K. J. Davis,
M. L. Pitt,
J. W. Ezzell, and A. M. Friedlander.
1995.
Pathology of experimental inhalation anthrax in the rhesus monkey.
Lab. Investig.
73:691-702[Medline].
|
| 13.
|
Fusco, P. C.,
F. Michon,
J. Y. Tai, and M. A. Blake.
1997.
Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates.
J. Infect. Dis.
175:364-372[Medline].
|
| 14.
|
Geiman, Q. M., and M. H. Meagher.
1967.
Susceptibility of a New World monkey to Plasmodium falciparum from man.
Nature
215:437-439[Medline].
|
| 15.
|
Handt, L. K.,
H. J. Klein,
H. Rozmiarek,
J. G. Fox,
W. J. Pouch, and S. L. Motzel.
1995.
Evaluation of two commercial serologic tests for the diagnosis of Helicobacter pylori infection in the rhesus monkey.
Lab. Anim. Sci.
45:613-617[Medline].
|
| 16.
|
Hankins, G. D.,
C. L. Lowery,
R. T. Scott,
W. R. Morrow,
K. D. Carey,
M. M. Leland, and E. V. Colvin.
1990.
Transplacental transfer of zidovidine in the near term pregnant baboon.
Am. J. Obstet. Gynecol.
163:728-732[Medline].
|
| 17.
|
Hendrickx, A. G.
1971.
Embryology of the baboon, p. 3-30.
University of Chicago Press, Chicago, Ill
|
| 18.
|
Hicks, J. T.,
J. L. Sullivan, and P. Albrecht.
1977.
Immune responses during measles infection in immunosuppressed rhesus monkeys.
J. Immunol.
119:1452-1456[Abstract/Free Full Text].
|
| 19.
|
Huang, C.,
P. M. Chen,
J. K. Kno,
W. H. Chin,
S. T. Lin, and Y. C. Lin.
1962.
Experimental whooping cough.
N. Engl. J. Med.
266:105-111.
|
| 20.
|
Hubbard, G. B.,
D. R. Lee,
J. W. Eichberg,
B. J. Gormus,
K. Xu, and W. M. Meyers.
1991.
Spontaneous leprosy in a chimpanzee (Pan troglodytes).
Vet. Pathol.
28:546-548[Medline].
|
| 21.
|
Jaax, N. K.,
K. J. Davis,
T. J. Geisbert,
P. Vogel,
G. P. Jaax,
M. Topper, and P. B. Jahrling.
1996.
Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure.
Arch. Pathol. Lab.
120:140-155.
|
| 22.
|
Kennedy, R. C.,
J. W. Eichberg,
R. E. Lanford, and G. R. Dreesman.
1986.
Anti-idiotypic antibody for type B viral hepatitis in chimpanzees.
Science
232:220-223[Abstract/Free Full Text].
|
| 23.
|
Kennedy, R. C.,
M. H. Shearer, and W. H. Hildebrand.
1997.
Nonhuman primate models to evaluate vaccine safety and immunogenicity.
Vaccine
15:903-908[Medline].
|
| 24.
|
Kennedy, R. C.,
M. H. Shearer,
W. H. Hildebrand, and R. S. Simmonds.
1997.
Nonhuman primates and their potential use in immunologically based investigations.
Immunologist
5:5-10.
|
| 25.
|
Krawczynski, K., and D. W. Bradley.
1989.
Enterically transmitted non-A, non-B hepatitis: identification of virus-associated antigen in experimentally infected cynomolgus macaques.
J. Infect. Dis.
159:1042-1049[Medline].
|
| 26.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during assembly of the head of bacteriophage T4.
Nature
227:680-685[Medline].
|
| 27.
|
Lankas, G. R., and R. D. Jensen.
1987.
Evidence of hepatitis A infection in immature rhesus monkeys.
Vet. Pathol.
24:340-344[Abstract].
|
| 28.
|
Larsen, J. W.,
W. F. London,
A. E. Palmer,
J. W. Tossell,
R. A. Bronsteen,
M. Daniels,
B. L. Curfman, and J. L. Sever.
1978.
Experimental group B streptococcal infection in the rhesus monkey. I. Disease production in the neonate.
Am. J. Obstet. Gynecol.
132:686-690[Medline].
|
| 29.
|
LeDuc, J. W.,
S. M. Lemon,
C. M. Keenan,
R. R. Graham,
R. Marchwicki, and L. N. Binn.
1983.
Experimental infection of the New World owl monkey (Aotus trivirgatus) with hepatitis A virus.
Infect. Immun.
40:766-772[Abstract/Free Full Text].
|
| 30.
|
Lemon, S. M.,
L. N. Binn,
R. Marchwicki,
P. C. Murphy,
L. H. Ping,
R. W. Jansen,
L. V. Asher,
J. T. Stapleton,
D. G. Taylor, and J. W. LeDuc.
1990.
In vivo replication and reversion to wild type of a neutralization-resistant antigenic variant of hepatitis A virus.
J. Infect. Dis.
161:7-13[Medline].
|
| 31.
|
Lkyllouriotis, P.,
M. Lkyllouriotis-Lazarou,
S. Natter,
R. Steiner,
S. Spitzauer,
S. Kapiotis,
P. Valent,
A. M. Hirschl,
S. E. Guber,
G. Laufer,
G. Wollenek,
E. Wolner,
M. Wimmer, and R. Valenta.
1999.
IgG subclass reactivity to human cardiac myosin in cardiomyopathy patients is indicative of a Th1-like autoimmune disease.
Clin. Exp. Immunol.
115:236-247[Medline].
|
| 32.
|
Martin, L. N.
1982.
Chromatographic fractionation of rhesus monkey (Macaca mulatta) IgG subclasses using DEAE cellulose and protein A-sepharose.
J. Immunol. Methods
50:319-329[Medline].
|
| 33.
|
Mattila, P. S.,
J. Pelkonen, and O. Makela.
1986.
Proportions of IgG subclasses in antibodies formed during vaccination with hepatitis B surface antigen.
Scand. J. Immunol.
24:699-704[Medline].
|
| 34.
|
Morell, A.,
B. Roth-Wicky, and F. Skvaril.
1983.
Immunoglobulin G subclass restriction of antibodies against hepatitis B surface antigen.
Infect. Immun.
39:565-568[Abstract/Free Full Text].
|
| 35.
|
Nagao, A. T.,
C. C. Martinez,
V. S. Vieira,
O. A. Takano,
B. T. Costa-Carvalho, and M. M. Carneiro-Sampaio.
1998.
Placental transfer of IgG and IgG subclass antibodies to anti-purified Escherichia coli LPS O16, O6, and O111.
Scand. J. Immunol.
47:609-614[Medline].
|
| 36.
|
Novembre, F. J.,
M. Saucier,
D. C. Anderson,
S. A. Klumpp,
S. P. O'Neil,
C. R. Brown II,
C. E. Hart,
P. C. Guenthner,
R. B. Swenson, and H. M. McClure.
1997.
Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1.
J. Virol.
71:4086-4091[Abstract].
|
| 37.
|
Onderdonk, A. B., and R. C. Kennedy.
1998.
Use of animal models for vaccine development, p. 19-42.
In
L. C. Paoletti, and P. McInnes (ed.), Vaccines: from concept to clinic. A guide to the development and testing of vaccines for human use. Harvard Medical Press, Cambridge, Mass
|
| 38.
|
Paoletti, L. C.,
R. C. Kennedy,
T. C. Chanh, and D. L. Kaspar.
1996.
Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons.
Infect. Immun.
64:677-679[Abstract].
|
| 39.
|
Pauerstein, C. J.,
C. A. Eddy,
H. D. Croxatto,
R. Hess,
T. M. Siler-Khodr, and H. B. Croxatto.
1978.
Temporal relationships of estrogen, progesterone and lutenizing hormone levels to ovulation in women and infrahuman primates.
Am. J. Obstet. Gynecol.
130:876-886[Medline].
|
| 40.
| Rossi, M. E., C. Azzari, M. Resti, C. Appendino, P. Pezzati, and A. Vierucci. Selectivity in IgG subclass response to
hepatitis B vaccine in infants born to HBsAg-positive mothers. Clin.
Exp. Immunol. 72:196-200.
|
| 41.
|
Rubens, C. E.,
H. V. Raff,
J. C. Jackson,
E. Y. Chi,
J. T. Bielitzki, and R. L. Hillier.
1991.
Pathophysiology and histopathology of group B streptococcal sepsis in Macaca nemestrina primates induced after intraamniotic inoculation: evidence for bacterial cellular invasion.
J. Infect. Dis.
164:320-330[Medline].
|
| 42.
|
Rzepczyk, C. M.,
K. Hale,
N. Woodroffe,
A. Bobogare,
P. Csurhes,
A. Ishii, and A. Ferrante.
1997.
Humoral immune responses of Solomon Islanders to the merozoite surface antigen 2 of Plasmodium falciparum show pronounced skewing towards antibodies of the immunoglobulin G3 subclass.
Infect. Immun.
65:1098-1100[Abstract].
|
| 43.
|
Sauer, L. W., and L. Hambrecht.
1929.
Experimental whooping cough.
Am. J. Dis. Child.
37:732-744[Abstract/Free Full Text].
|
| 44.
|
Shearer, M. H.,
A. H. Lucas,
P. W. Anderson,
K. D. Carey,
H. B. Jenson,
T. C. Chanh,
J. R. Stanley, and R. C. Kennedy.
1997.
The baboon as a nonhuman primate model for assessing the effects of maternal vaccination with Haemophilus influenzae type b polysaccharide vaccines.
Infect. Immun.
65:3267-3270[Abstract].
|
| 45.
|
Shearer, M. H.,
F. J. Stevens,
F. A. Westholm,
H. B. Jenson,
T. C. Chanh,
K. D. Carey,
G. L. White,
A. Solomon, and R. C. Kennedy.
1995.
Serologic crossreactions among primate immunoglobulins.
Dev. Comp. Immunol.
19:547-557[Medline].
|
| 46.
|
Shevtsova, Z. V.,
B. A. Lapin,
N. V. Doroshenko,
R. I. Krilova,
L. I. Korzaja,
I. B. Lomovskaya,
Z. N. Dzhelieva,
G. K. Zairov,
V. M. Stakhanova,
E. G. Belova, and L. A. Sazhchenko.
1988.
Spontaneous and experimental hepatitis A in Old World monkeys.
J. Med. Primatol.
17:177-194[Medline].
|
| 47.
|
Shope, T.,
D. Dechairo, and G. Miller.
1973.
Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus.
Proc. Natl. Acad. Sci. USA
70:2487-2491[Abstract/Free Full Text].
|
| 48.
|
Sousa, A. O.,
S. Henry,
F. M. Maroja,
F. K. Lee,
L. Brum,
M. Singh,
P. H. Lagrange, and P. Aucouturier.
1998.
IgG subclass distribution of antibody responses to protein and polysaccharide mycobacterial antigens in leprosy and tuberculosis patients.
Clin. Exp. Immunol.
111:48-55[Medline].
|
| 49.
|
Stevens, V. C.,
S. J. Sparks, and J. E. Powell.
1990.
Levels of estrogens, progestogens and luteinizing hormone during the menstrual cycle of the baboon.
Endocrinology
87:658-666[Abstract/Free Full Text].
|
| 50.
|
Taylor, R. R.,
S. J. Allen,
B. M. Greenwood, and E. M. Riley.
1998.
IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria.
Am. J. Trop. Med. Hyg.
58:406-413[Abstract].
|
| 51.
|
Ticehurst, J.,
L. L. Rhodes,
K. Krawczynski,
L. V. Asher,
W. F. Engler,
T. L. Mensing,
J. D. Caudill,
M. H. Sjogren,
C. H. Hoke,
J. W. LeDuc,
J. W. Bradley, and L. N. Binn.
1992.
Infection of Owl monkeys (Aotus trivirgatus) and cynomolgus monkeys (Macaca fascicularis) with hepatitis E virus from Mexico.
J. Infect. Dis.
165:835-845[Medline].
|
| 52.
|
Vaslin, B.,
J. M. Claverie,
O. Benveniste,
F. C. Baree-Sinoussi, and D. Dormont.
1994.
Nef and gag synthetic peptide priming of antibody responses to HIV type antigens in mice and primates.
AIDS Res. Hum. Retroviruses
10:1241-1250[Medline].
|
| 53.
|
Warren, J. T., and M. A. Levinson.
1995.
Fourth annual survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates.
J. Med. Primatol.
24:150-168[Medline].
|
| 54.
|
Watts, A. M.,
J. R. Stanley,
M. H. Shearer,
P. S. Hefty, and R. C. Kennedy.
1999.
Fetal immunization of baboons induces a fetal specific antibody response.
Nat. Med.
5:427-430[Medline].
|
| 55.
|
Watts, A. M.,
J. R. Stanley,
M. H. Shearer, and R. C. Kennedy.
1998.
Maternal and fetal vaccination strategies for hepatitis B surface antigen in nonhuman primate models: evaluation of therapeutic modalities during pregnancy, p. 185-193.
In
R. F. Schinaze, J. P. Sommadossi, and H. C. Thomas (ed.), Therapies for viral hepatitis. International Medical Press, London, United Kingdom
|
| 56.
|
Yole, D. S.,
R. Pemberton,
G. D. Reid, and R. A. Wilson.
1996.
Protective immunity to Schistosoma mansoni induced in the olive baboon Papio anubis by the irradiated cercaria vaccine.
Parasitology
112:37-46.
|
| 57.
|
Young, L. S.,
S. Finerty,
L. Brooks,
F. Scullion,
A. B. Rickinson, and A. J. Morgan.
1989.
Epstein-Barr virus expression in malignant lymphomas induced by experimental virus infection of cottontop tamarins.
J. Virol.
63:1967-1974[Abstract/Free Full Text].
|
| 58.
|
Young, M. D.,
J. A. Porter, and C. P. Johnson.
1966.
Plasmodium vivax transmitted from monkey to man.
Science
153:1006-1007[Abstract/Free Full Text].
|
Clinical and Diagnostic Laboratory Immunology, November 1999, p. 953-958, Vol. 6, No. 6
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Stacy, S., Pasquali, A., Sexton, V. L., Cantwell, A. M., Kraig, E., Dube, P. H.
(2008). An Age-Old Paradigm Challenged: Old Baboons Generate Vigorous Humoral Immune Responses to LcrV, A Plague Antigen. J. Immunol.
181: 109-115
[Abstract]
[Full Text]
-
Williamson, E. D., Hodgson, I., Walker, N. J., Topping, A. W., Duchars, M. G., Mott, J. M., Estep, J., LeButt, C., Flick-Smith, H. C., Jones, H. E., Li, H., Quinn, C. P.
(2005). Immunogenicity of Recombinant Protective Antigen and Efficacy against Aerosol Challenge with Anthrax. Infect. Immun.
73: 5978-5987
[Abstract]
[Full Text]
-
Phipps, A. J., Premanandan, C., Barnewall, R. E., Lairmore, M. D.
(2004). Rabbit and Nonhuman Primate Models of Toxin-Targeting Human Anthrax Vaccines. Microbiol. Mol. Biol. Rev.
68: 617-629
[Abstract]
[Full Text]
-
Coban, C., Philipp, M. T., Purcell, J. E., Keister, D. B., Okulate, M., Martin, D. S., Kumar, N.
(2004). Induction of Plasmodium falciparum Transmission-Blocking Antibodies in Nonhuman Primates by a Combination of DNA and Protein Immunizations. Infect. Immun.
72: 253-259
[Abstract]
[Full Text]
-
Locher, C. P., Witt, S. A., Herndier, B. G., Abbey, N. W., Tenner-Racz, K., Racz, P., Kiviat, N. B., Murthy, K. K., Brasky, K., Leland, M., Levy, J. A.
(2002). Increased Virus Replication and Virulence after Serial Passage of Human Immunodeficiency Virus Type 2 in Baboons. J. Virol.
77: 77-83
[Abstract]
[Full Text]
-
Hefty, P. S., Brooks, C. S., Jett, A. M., White, G. L., Wikel, S. K., Kennedy, R. C., Akins, D. R.
(2002). OspE-Related, OspF-Related, and Elp Lipoproteins Are Immunogenic in Baboons Experimentally Infected with Borrelia burgdorferi and in Human Lyme Disease Patients. J. Clin. Microbiol.
40: 4256-4265
[Abstract]
[Full Text]